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ABSTRACT
In non-malignant RWPE-1 prostate epithelial cells
signaling by the nuclear receptor Vitamin D
Receptor (VDR, NR1I1) induces cell cycle arrest
through targets including CDKN1A (encodes
p21
(waf1/cip1)). VDR dynamically induced individual
histone modification patterns at three VDR binding
sites (R1, 2, 3) on the CDKN1A promoter. The mag-
nitude of these modifications was specific to each
phase of the cell cycle. For example, H3K9ac enrich-
ment occurred rapidly only at R2, whereas parallel
accumulation of H3K27me3 occurred at R1; these
events were significantly enriched in G1 and S
phase cells, respectively. The epigenetic events
appeared to allow VDR actions to combine with
p53 to enhance p21
(waf1/cip1) activation further. In
parallel, VDR binding to the MCM7 gene induced
H3K9ac enrichment associated with rapid mRNA
up-regulation to generate miR-106b and conse-
quently regulate p21
(waf1/cip1) expression. We
conclude that VDR binding site- and promoter-
specific patterns of histone modifications combine
with miRNA co-regulation to form a VDR-regulated
feed-forward loop to control p21
(waf1/cip1) expression
and cell cycle arrest. Dissection of this feed-forward
loop in a non-malignant prostate cell system
illuminates mechanisms of sensitivity and therefore
possible resistance in prostate and other VDR
responsive cancers.
INTRODUCTION
Collectively, nuclear receptors (NRs) regulate a signiﬁcant
proportion of the human genome to exert diverse cellular
function. Several NRs are attractive chemotherapy targets
as the gene programs they control broadly inhibit cell
proliferation and/or induce programmed cell death.
For example, the anticancer actions of 1a,25(OH)2D3,
the natural VDR (NR1I1) ligand, have been established
for 30 years (1–3) and in certain cancer cell types including
some prostate cancer cell lines (4–7), and xenograft and
transgenic prostate cancer models (8,9). These effects are
not universal and insensitivity is also apparent (10,11).
In parallel, large-scale epidemiological studies found
inverse associations between circulating levels of the
pre-ligand, 25OH-D3, and prostate cancer risk (12–20).
However, despite these links between VDR signaling and
broad anticancer activities, clinical exploitation in cancer
has been slow.
Gene target expression by NRs has been intensively
investigated from the perspective of receptor binding to
response elements (21–24). These dynamics contribute to
the patterns of target gene mRNA, however, the cycles
vary considerably in timing and magnitude of response
between different target genes and NRs. A complete
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patterns and their biological signiﬁcance remain elusive.
Against this backdrop, elucidating NR gene expression
control mechanisms is important to illuminate mechan-
isms of resistance in cancer cells. In particular epigenetic
resistance mechanisms have been explored. For example
elevated levels of the NCOR2/SMRT co-repressor
suppress VDR’s ability to regulate a subset of target
genes that mediate antiproliferative actions (25–27).
In turn the accumulation of repressive histone modiﬁca-
tions at suppressed target genes may allow for
hypermethylation at adjacent CpG regions (28) and devel-
opment of stable patterns of gene silencing [reviewed in
refs. (29,30)].
MiRNA also contribute negative regulatory aspects to
normal gene regulation, for example, as part of feed-
forward loop motifs (31,32). Also NRs, including the
VDR, are able to govern miRNA expression, and this in
turn may contribute to resistance (33–37). The extent to
which NR-regulated miRNA form feed-forward loops
remains uncertain. Previously, we established that
1a,25(OH)2D3 regulates the DNA helicase MCM7 (25)
and others have established that miR-106b, located on
intron 13 of the MCM7 gene, inhibits the VDR target
gene, CDKN1A (encodes p21
(waf1/cip1)) (38,39). Together
these ﬁndings suggest that co-regulated miRNA may form
an integral part of VDR signaling to control gene
expression.
To investigate how VDR-regulated epigenetic events
control target gene expression, we interrogated non-
malignant RWPE-1 prostate epithelial cells (40) undergo-
ing G1 cell cycle arrest in response to 1a,25(OH)2D3
[reviewed in ref. (41)]. Speciﬁcally, we undertook a series
of experiments to establish, if and to what extent VDR
governed both histone modiﬁcations and miRNA
expression to control gene expression. We focused on
the circuitry that controls the CDKN1A gene and
revealed that mRNA and protein modulation was
determined by the spatial-temporal binding sequence of
the VDR complex to two target genes; namely
the CDKN1A gene itself and the MCM-7 gene that gives
rise to the miR-106b cluster. In this manner, p21
(waf1/cip1)
regulation arises due to the interplay of three processes:
(i) gene- and response element-speciﬁc VDR-induced
histone modiﬁcations, (ii) cell cycle status and (iii) co-
regulation of miR-106b. These events generate a VDR
feed-forward loop that regulates the magnitude, timing
and sensitivity of p21
(waf1/cip1) expression and hence
cell cycle arrest. The regulation and function of
this feed-forward loop provides insight into mechanisms
of VDR sensitivity and resistance in prostate other
VDR-responsive cancers.
MATERIALS AND METHODS
Agents, cell culture and antibodies
1a25(OH)2D3 [gift of Dr Milan Uskokovic (BioXell
S.p.A., Italy)] used at 100nM concentration for all experi-
ments. RWPE-1 non-malignant prostate epithelial cells
and RWPE-2 cells were maintained in KSF media
supplemented with EGF and BPE (Invitrogen, Paisley,
UK). P69SV40T cells were cultured in RPMI with
10% FCS.
Antibodies for immunoblot: p21
(waf1/cip1), beta-actin
(Abcam, ab7960, ab8229). Antibodies for ChIP
assays—VDR, NCOR1, RNA Pol II (Abcam ab3508,
ab24552, ab26721), NCOR2/SMRT (Santa Cruz
Biotechnologies sc1610), H3K27me3 (Upstate ABE44),
H3K9ac, H3K9me2 and H3K4me3 [in house
antibodies (42)]
Mice
Wild-type C57 BL/6xFVB mice were treated with EtOH
or 20mg/kg 1a,25(OH)2D3 for 12 or 24h. Nine mice were
used per treatment group. Prostate tissues pooled into
three groups of three. RNA was isolated using TRIzol
(Invitrogen).
Live cell sorting
Cells were stained with Hoechst 33342 (Invitrogen), which
is a well-tolerated stain for DNA(43), fractionated using a
MoFlo cell sorter (Beckman-Coulter, High Wycombe,
UK) and Summit V4.3 software (Beckman-Coulter, UK)
and 510
5 cells/phase were collected.
q-RT–PCR
RNA was isolated using TRizol (Invitrogen). Target
gene expression was quantitated on an ABI 7900
[Applied Biosystems (http://www.appliedbiosystems
.com)] machine. All primers and probes were as described
previously (25). For miRNA quantitation, q-PCR was
performed using Assay-on-Demand miR-106b and
RNU48 probes. Measurements were performed in
technical and biological triplicate.
Immunoblot analysis
Fifty microgram total protein extracts separated on 10%
SDS gels, and blots probed with antibodies described
above. Proteins detected using ECL (Amersham) and
autoradiography.
ChIP protocols
X-ChIP was used to measure the association of VDR,
NCOR1 and NCOR2/SMRT and RNA Pol II binding
as described previously (44). Brieﬂy, chromatin from
1.510
6 mid-exponential cells was cross-linked. Pre-
cleared inputs were immunoprecipited with: VDR
(Abcam ab3508), NCOR1 (Abcam ab24552),
NCOR2/SMRT (Santa Cruz 1610), RNA Pol II (Abcam
ab26721). Complexes were recovered using magnetic
beads, washed, crosslinking reversed and further cleared
DNA was recovered by standard precipitation
approaches. Twenty-ﬁve nanogram DNA was used per
Q-PCR reaction using SYBRgreen with pre-optimized
primers (Table 1). To measure the interaction of VDR
with co-repressors Re-ChIP was used. VDR immuno-
complexes prepared with the VDR indicated in the
X-ChIP section were eluted and immunoprecipitated
with antibodies to NCOR1 or NCOR2/SMRT, new
2046 Nucleic Acids Research, 2011,Vol.39, No. 6immuno-complexes were formed and detection was as
indicated for X-ChIP. N-ChIP was performed as previ-
ously described (45). Brieﬂy, chromatin from 510
7cells
was harvested from nuclei and digested by micrococcal
nuclease (Pharmacia, Milton Keynes, UK) and
immunoprecipited with H3K27me3 (Upstate) (Abcam
ab27472) or H3K9ac, H3K9me2 and H3K4me3 [in
house antibodies (42)] or IgG control. DNA was
puriﬁed and analyzed as for X-ChIP. C-ChIP was
adapted from N-ChIP as previously described (46) by
‘spiking’ with SL2 cells prior to chromatin extraction
and using human speciﬁc primers (Table 1).
MiR-106b knockdown
si-miR-106b (MI0000734, Dharmacon) and scrambled
constructs (IN-001005-01-05, Dharmacon) transiently
transfected into cells at 100nM. Cells seeded into 6-well
plates for treatment with EtOH or 1a,25(OH)2D3
(100nM) and RNA isolated using TRizol (Invitrogen).
For FACS analysis, cells were stained with Propidium
Iodide solution, and run through a FACScan
II (Becton Dickinson Biosciences). DNA histograms
were analyzed using ModFit software (Verity Software
House).
RESULTS
1a,25(OH)2D3 induces cell cycle arrest associated with
dynamic target gene regulation
1a,25(OH)2D3 induced cell cycle arrest in RWPE-1 cells
after 24h exposure to ligand (Supplementary Figure S1).
Co-incident with the cell cycle arrest, known VDR target
genes (23,39,47,48) revealed signiﬁcant 1a,25(OH)2D3-
induced regulation, in bulk cell populations, compared
to EtOH time-matched controls (Figure 1A). These
patterns of mRNA accumulation were not readily
predicted from the arrangement and location of vitamin
D response elements (VDREs) in the promoter regions
(23,39,47). These analyses suggested common and
unique aspects of mRNA regulation. CDKN1A,
GADD45A and IGFBP3 displayed rapid modulation
that returned to basal levels whereas CYP24A1 displayed
more sustained accumulation to a greater magnitude.
CYP24A1, GADD45A and CDKN1A all displayed
sequential repression, accumulation at 0.5h, followed by
repression. IGFBP3 displayed no repression, but instead
more immediate accumulation. Post 1h, all genes
displayed modulating accumulation with some degree
of synchrony at 2h that was generally reduced subse-
quently, although another peak was generally apparent
at 12h. P21
(waf1/cip1) (encoded by CDKN1A) expression
displayed distinct peaks at 1 and 3h and a broader peak
from 16h onwards reﬂecting increased mRNA levels at
0.5, 2 and 12h (Figure 1B). The dynamic regulation of
CDKN1A over the ﬁrst 1h was also observed in the
RAS-transformed variant of RWPE-1 cells, namely
RWPE-2 (40) and in another prostate epithelial
immortalized cell line, namely P69SV40T (49). These
common VDR-regulated mRNA accumulation patterns
in different prostate epithelial cell models suggest the
mechanisms underlying this behavior are also common
and shared (Supplementary Figure S2).
VDR-regulated histone modiﬁcations underpin CDKN1A
regulation
Time-resolved quantitative ChIP approaches (0.5, 1, 4 and
12h) at three VDRE regions (R1, R2, R3) (Figure 2A)
(39). The spatial–temporal re-distribution of VDR and
co-repressors was measured in parallel with regulation of
a panel of histone modiﬁcations. Histone modiﬁcations
measured were associated with either gene maintenance,
namely H3K4me3 (the trithorax mark) and H3K27me3
(the polycomb mark), or others associated with dynamic
regulation of transcription (H3K9ac and H3K9me2).
These approaches revealed that 1a,25(OH)2D3 induced
tightly regulated gene activating epigenetic events at only
one response element on CDKN1A, namely R2 [from
4505 to 4489 from transcription start site (TSS)]
(Figure 2B).
VDR accumulated rapidly at R2 after 0.5 and 1h in
response to 1a,25(OH)2D3 treatment and was associated
with release of both co-repressors at 0.5h (Figure 2B).
N-ChIP approaches revealed parallel enrichment of
H3K9ac and loss of repressive H3K9me2 at 0.5h.
At this time point, at the other response elements,
Table 1. Primer sequences used for Q-PCR and ChIP analyses





MCM7, –7995 TACTTGGGAGGCTGAGATGG CAGGCTGGAGTGCAGTGTTA
MCM7, –589 CCTAGCCCACCCAACCTTAT TAATTCACAGTGCCCACAGG
CDKN1A, –7049 (R3) AGCAGCACTGAAGCCTAACC GAGAGGCCTACCAGCTTCAG
CDKN1A, –4496 (R2) TAGAGATGCTCAGGCTGCTG AGAGCTTCACCGACATAGCC
CDKN1A, –2137 (R1) GAGGAAGGGGATGGTAGGAG CTGGCAGATCACATACCCTGT
CDKN1A, TSS TATATCAGGGCCGCGCTG GGCTCCACAAGGAACTGACTTC
C-ChIP
CDKN1A, TSS CCGAAGTCAGTTCCTTGTGG CGCTCTCTCACCTCCTCTGA
CDKN1A, –2137 (R1) GCCTGTTTTCAGGTGAGGAA CTGGCAGATCACATACCCTGT
Nucleic Acids Research,2011, Vol.39, No. 6 20471a,25(OH)2D3 actively induced association with
co-repressor and/or enriched for repressive histone modi-
ﬁcations. Thus signiﬁcant enrichment of NCOR2/SMRT
occurred at R3 (from 7059 to 7036) and of NCOR1 at
R1 (from 2146 to 2129), the latter is associated with a
loss of H3K9ac and enrichment of H3K9me2.
The activation state at R2 was rapid and reversed after
1h. Thus following the initial accumulation at 0.5h of an
Figure 1. Dynamic regulation of VDR target genes. (A) RWPE-1 cells were treated with 1a,25(OH)2D3 (100nM) or EtOH and mRNA was extracted
at the indicated time points, and accumulation of indicated genes measured by TaqMan Q-RT–PCR. Accumulation of each target is given as log2
(fold change). Each data point represents the mean of triplicate experiments in triplicate wells ±SEM (*P<0.05, **P<0.01, ***P<0.001).
All measurements performed in technical and biological triplicate. (B) Total cell proteins were isolated from cells treated as above at the indicated
time points (+D3) and subjected to western immunoblotting. Representative blots are shown for p21
(waf1/cip1) (Abcam, ab7960). b-Actin used as a
loading control (Abcam, ab8229). For quantiﬁcation of signal Odyssey infrared imaging system (LI-COR, Lincoln, NE) was used and the quan-
tiﬁcation for the fold changes are under each image.
2048 Nucleic Acids Research, 2011,Vol.39, No. 6CDKN1A
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Figure 2. VDR-regulated epigenetic events on the promoter of CDKN1A. (A) The genomic location of the VDR binding regions (R3, R2 and R1)
on CDKN1A and the transcription start site (TSS). (B) Left graphs. RWPE-1 bulk populations treated with 1a,25(OH)2D3 (100nM) or EtOH for
indicated time points. Association of RNA Pol II, VDR, NCOR1 and NCOR2/SMRT was measured at each region by X-ChIP using ChIP grade
antibodies and normalized and given as fold enrichment over input as described previously (44). Primers are shown in Table 1. Enrichment was
measured by Q-PCR with primers speciﬁc to these regions that ampliﬁed a product <150bp. Right graphs. Parallel changes to histone modiﬁcations
(H3K9me2, H3K27me3, H3K4me3 and H3K9ac) were assayed using N-ChIP and normalized using bound over unbound DNA pulled down with
speciﬁc ChIP grade antibodies (42). N-ChIP was performed as previously described (53). Enrichment was measured by Q-PCR as above. All
measurements performed in technical duplicate and biological triplicate.
Nucleic Acids Research,2011, Vol.39, No. 6 2049‘active’ receptor and epigenetic signature (Figure 2B) and
mRNA and protein accumulation (Figure 1),
NCOR2/SMRT and H3K9me2 were re-enriched for 1h
at R2, with loss of H3K9ac levels, underscoring the tight
control of these activation events. In contrast, the repres-
sive events at R3 and R1 were more sustained, notably at
R1 where H3K27me3 accumulated from 1h onwards
through to 12h (Figure 2B). It is also interesting to note
that NCOR/SMRT enrichment appears to move along the
promoter from R3 (0.5h) to R2 (1h) to R1 (12h) also
suggesting longer term effects on the promoter. The TSS
also displayed sustained H3K4me3 enrichment after
0.5h as NCOR1 and NCOR2/SMRT levels declined.
H3K4me3 enrichment continued to 12h, as did RNA
Pol II and accompanied mRNA and protein accumulation
at 12h.
Re-ChIP analyses were undertaken at R2 and R1
as these regions reﬂected the parallel but distinct activa-
tion and repression observed upon 1a,25(OH)2D3 treat-
ment. These analyses under scored the role of
co-repressor release and recapture. NCOR1 interactions
with VDR were signiﬁcantly reduced at both regions
after 0.5h although this was only co-incident
with H3K9ac gain at R2 (Figure 3A). Subsequently,
NCOR1 signiﬁcantly re-associated with VDR, most
noticeably at R2, at 1h onwards, co-incident with
increased H3K9me2 in this region (Figure 2). NCOR2/
SMRT did not dissociate from the VDR, but rather
trended to accumulation at 4h at R2 and reﬂected the
co-repressor enrichment in this region at this time point
(Figure 2).
At certain time points the CDKN1A locus displayed
both activating and repressing histone modiﬁcations,
whereas mRNA expression was at basal levels.
For example, after 1h the TSS and body of the gene
displayed enrichment for H3K9ac and H3K4me3
(Figure 2 and data not shown), whereas regions R2 and
R1 were enriched for H3K9me2 and H3K27me3, respect-
ively. We investigated whether this represented a so-called
poised state and whether the CDKN1A locus could
be activated by further transcriptional activators.
Regions R1 and R2 are within close proximity to
p53 binding sites (39,50). We therefore tested if the p53
activator 5-ﬂurouracil enhanced 1a,25(OH)2D3-induced
CDKN1A mRNA accumulation over a 4h time course
and revealed signiﬁcantly co-operative actions at 1h
(Figure 3B). The combination of agents yielded a signiﬁ-
cant combined effect at 1h; comparable events were
observed with IGFBP3, another target regulated by
VDR and p53 (Figure 3B) (51).
Figure 3. VDR interactions with co-repressors and the enhancement of 1a,25(OH)2D3-induced target gene expression. (A) RWPE-1 cells were
treated as above, and X-ChIP performed and VDR DNA–protein complexes were eluted and immunoprecipitated with antibodies to NCOR1 or
NCOR2/SMRT. Enrichment was measured by Q-PCR with primers speciﬁc to these regions that ampliﬁed a product less than 150bp. Primers are
shown in Table 1. All measurements performed in technical duplicate and biological triplicate. (B) RWPE-1 cells were treated with 1a,25(OH)2D3
(100nM), 5-ﬂurouracil (Fl-U) (50nM), or combination (DF) for 1h. Accumulation of CDKN1A and IGFBP3 measured by TaqMan Q-PCR. All
measurements performed in technical and biological triplicate (*P<0.05, **P<0.01, ***P<0.001).
2050 Nucleic Acids Research, 2011,Vol.39, No. 6Cell cycle status determines the magnitude of histone
modiﬁcations on the CDKN1A promoter
Previous Q-PCR approaches in FACS-sorted RWPE-1
cells revealed S-phase elevation of co-repressors (for ex-
ample NCOR1, NCOR2/SMRT) and HDACs (for
example HDACs 2 and 3), whereas VDR and was
broadly equivalent through the cell cycle [(52) and data
not shown]. We therefore reasoned that the mixture of
activating and repressing histone modiﬁcations may
represent cells in different cell cycle states, for example,
that S-phase cells would not be epigenetically responsive
to VDR activation. To address this possibility, we FACS-
sorted cells into different phases of the cell cycle and
examined VDR-induced changes in histone modiﬁcations
through the cell cycle using Carrier-ChIP (C-ChIP)
approaches (53) (Figure 4).
Again, focusing on two response regions that displayed
distinct activation events at 0.5h, we revealed that after
0.5h, 1a,25(OH)2D3 induced signiﬁcant H3K27me3
enrichment at R1 in S and G2/M phase cells only
(Figure 4A). At the basal level there were two pronounced
differences in G1 cells compared to the other phases, with
H3K9ac enrichment at R1 at the TSS (data not shown).
Interestingly in bulk culture upon treatment with
1a,25(OH)2D3 H3K27me3 levels trended to enrichment
after 0.5h, however it was not signiﬁcant, but this
became signiﬁcant when considering the individual
phases of the cell cycle. Similar phase-speciﬁc patterns of
H3K9ac enrichment occurred in G1 cells only at the TSS,
and again this was not signiﬁcant when considering bulk
population cells but was when considering G1 phase cells
only (Figure 4B).
Co-regulation of miR-106b is critical to regulate
p21
(waf1/cip1)expression
1a,25(OH)2D3 treatment up-regulated MCM7, and conse-
quently miR-106b, in a highly similar manner to
CDKN1A. That is, MCM7 accumulated at 0.25h,
miR-106b at 0.33h, prior to the initial CDKN1A expres-
sion at 0.5h (Figure 5A). Two VDR binding regions on
the MCM7 promoter were identiﬁed in silico and
demonstrated the same rate of VDR binding over the
ﬁrst 0.5h compared to R2 of CDKN1A (Figure 5B).
We also examined the enrichment of the same four
histone modiﬁcations as measured at the CDKN1A
promoter and found that only H3K9ac was clearly
enriched at 7995 (0.5h) and the TSS (1h) (Figure 5C).
In contrast the repressive histone modiﬁcations
(H3K9me2 and H3K27me3) were not signiﬁcantly
altered at either the two VDR binding regions or the
TSS. These data suggest that MCM7 has an intrinsically
more responsive promoter. However, the rate is similar of
VDR binding kinetics to the critical activating response
elements, either R2 of the CDKN1A gene or at position
7995 of the MCM7 gene. Therefore the receptor binding
kinetics alone do not explain the altered mRNA accumu-
lation rate between the genes CDKN1A and MCM7
(Figure 5A).
Therefore, we investigated the contribution of
miR-106b to control p21
(waf1/cip1) expression and cell
cycle arrest. Firstly intervention with miRNA knockdown
approaches resulted in 50% knockdown and caused
1a,25(OH)2D3 treatment to induce CDKN1A accumula-
tion to the same extent, but at a signiﬁcantly earlier time
point (Figures 1A, 5A and D) thus suggesting a role to
control mRNA accumulation rates. In parallel, we estab-
lished that the same miRNA knockdown approaches
allowed p21
(waf1/cip1) to be induced to a higher level
(Figure 5E) leading to an enhanced 1a,25(OH)2D3
driven G1 arrest (Figure 5F). These data suggest that
miR-106b also plays a role in governing translation
rates, as the area under the curve of mRNA accumulation
did not differ signiﬁcantly with miR-106b siRNA
(Figure 5D). Interestingly at later time points (22h)
miR-106b also accumulated and appears to correlate
with the loss of p21
(waf1/cip1) expression after 22h
(Figure 1B and Supplementary Figure S3). Finally, the
relationship between Cdkn1a and miR-106b appears
Figure 4. The cell cycle determines the magnitude of VDR-regulated
histone modiﬁcation. RWPE-1 cells were treated with 1a,25(OH)2D3
(100nM) for 0.5h prior to being FACS-sorted into the different
phases of the cell cycle. Cells stained with Hoechst 33342
(Invitrogen), fractionated using a MoFlo cell sorter
(Beckman-Coulter, High Wycombe, UK) and Summit V4.3 software
(Beckman-Coulter, UK) and 510
5 cells/phase collected. Induced
changes to repressive (H3K27me3) and activating (H3K4me3 and
H3K9ac) histone modiﬁcations at R1 and the TSS on the CDKN1A
promoter were interrogated using Carrier-ChIP protocols, C-ChIP was
adapted from N-ChIP as previously described (46) by ‘spiking’ with
SL2 cells prior to chromatin extraction and using human speciﬁc
primers (Table 1). Histone modiﬁcations were assayed using N-ChIP
and normalized using bound over unbound DNA pulled down with
speciﬁc antibodies. Each data point represents the mean of triplicate
experiments in duplicate wells±S.E.M. (*P<0.05, **P<0.01).
Nucleic Acids Research,2011, Vol.39, No. 6 2051Figure 5. MiR-106b co-expression governs p21
(waf1/cip1) expression and cell cycle arrest. (A) RWPE-1 cells were treated with 1a,25(OH)2D3 (100nM)
or EtOH control for indicated time points, mRNA extracted, and levels of accumulation of indicated genes measured by TaqMan Q-PCR. For
miRNA quantitation, Q-PCR performed using Assay-on-Demand miR-106b and RNU48 probes. All measurements performed in technical and
biological triplicate. (B) Cells were treated as in A, chromatin extracted and VDR binding to the indicated VDREs in the MCM7 promoter, and R2
on the CDKN1A promoter was measured, as indicated in Figure 2. (C) Changes to H3K9ac were assayed using N-ChIP and normalized using bound
over unbound DNA pulled down with speciﬁc ChIP grade antibodies (42). N-ChIP was performed as previously described (53). Enrichment was
measured by Q-PCR as above. All measurements performed in technical and biological triplicate. (D) 100nM si-miR-106b (MI0000734, Dharmacon)
and scrambled constructs (IN-001005-01-05, Dharmacon) transiently transfected into cells. Following transfection, cells were treated as above.
CDKN1A mRNA expression was measured by TaqMan Q-PCR as in Figure 1A. All data points on panels A and D represent the mean of triplicate
experiments ampliﬁed in triplicate wells±SEM (*P<0.05, **P<0.01, ***P<0.005). (E) The effect of mir-106b knockdown on p21
(waf1/cip1)
expression. Cells were treated as in panel C and p21
(waf1/cip1) detected by western blot as in Figure 1B, and both scr and siRNA blots exposed
for 30 s. (F) The effect of 1a,25(OH)2D3 treatment on cell cycle arrest was measured in the indicated treatment groups. For FACS analysis, cells were
stained with Propidium Iodide solution and run through a FACScan II (Becton Dickinson Biosciences). DNA histograms were analyzed using
ModFit software (Verity Software House). Results were plotted as percent of cells seen in G1 phase and each data point represents the mean of three
separate experiments±SEM (*P<0.05, **P<0.01, ***P<0.005).
2052 Nucleic Acids Research, 2011,Vol.39, No. 6detectable in the prostates of normal C57 BL/6xFVB
mice at 12 and 24h post-treatment with 1a25(OH)2D3
(20mg/kg). Notably at 12h there was a signiﬁcant
increase in miR-106b and corresponding repression of
Cdkn1a (Figure 6).
DISCUSSION
Transcriptional kinetics, even for the same NRs, are
highly variable depending upon the cell type and target
gene. These ambiguities are compounded by the frequent
use of cancer cell lines to study these kinetics.
Problematically, these cells frequently contain corruptions
to the very mechanisms being studied, including elevated
NCOR1 and NCOR2/SMRT expression (25,26,54,55).
This is apparent when considering the VDR where, in
malignant systems, 1a,25(OH)2D3 induced CDKN1A ac-
cumulation appears highly variable, often being either sig-
niﬁcantly delayed or absent despite apparently adequate
receptor expression (44,56,57). Analogous studies on the
estrogen receptor a revealed rapid binding to target genes,
occurring in the order of minutes, but is non-functional as
it results in neither mRNA nor protein expression changes
(22,58). In contrast, other NRs, interrogated with different
technologies, have suggested highly rapid cycling (59).
The current study informs these debates by utilizing an
endogenous promoter, in a non-malignant cell system,
where the response to ligand approximates closely to a
normal response. Rapid and dynamic patterns of
mRNA accumulation occurred for four VDR target
genes, and there was a degree of response synchrony
especially in early events. We established for one target,
CDKN1A, that the patterns of mRNA accumulation
reﬂected receptor and co-repressor exchanges occurring
in a unique manner at each of three VDREs. In turn,
these events drove unique patterns of histone modiﬁca-
tions. Activation events occurred at only one response
element (R2) after 0.5h and were reﬂected by increased
mRNA accumulation and protein expression. It is
tempting to speculate that the immediate repressive
events occurring at R3 and R1 contribute to the reduced
mRNA levels for CDKN1A that occur at earlier time
points. Collectively, these results support the concept
that in non-malignant systems NR transcriptional
responses can be rapid and functional, and faithfully
lead to changes in protein. The transition through
activated epigenetic states appears to allow the integration
of transcriptional signals, for example through
co-operation with p53 at 1h and suggests an epigenetic
basis for the observed co-operation between these two
pathways (39,60–63). The co-operative effects at 1h also
support the p53 functional status of RWPE-1 cells and
reﬂects the fact human papillomavirus 18 (HPV 18)
immortalized cells do not necessarily target p53 (40).
We undertook univariate linear regression analyses to
identify patterns of associations within these data sets.
These approaches identiﬁed the most signiﬁcant associ-
ation occurred after 4h, where the locus appeared to
return to a resting state, characterized by a signiﬁcant
association at between VDR, NCOR1 and H3K27me3
(P<0.05) at the TSS and R1 (data not shown). These
ﬁndings support an emerging view of this histone mark
being more dynamically regulated than previously
appreciated (64,65) and suggest its regulation is part of
sequential epigenetic steps in the control of transcription.
These data suggest that the regulation of H3K27me3 at
speciﬁc response elements act as a marker of the return to
the basal state and forms part of a biological ratchet to
regulate dynamic transcriptional patterns (66).
We made the further discoveries that the magnitude of
epigenetic modulation was reﬁned by the cell cycle status.
ChIP approaches in FACS-sorted cells revealed that G1
phase cells were characterized by enhanced VDR-induced
activating histone modiﬁcations (for example H3K9ac),
with S and G2/M phases being largely repressive, for
example, with H3K27me3 enrichment at region R1.
Thus events, which were not signiﬁcant when considering
bulk populations, emerged with signiﬁcant clarity when
considering each speciﬁc cell cycle phase and underscore
the fact that bulk culture ﬁndings represent an average
event of potentially very different populations. While
other NRs have been demonstrated to display cell
cycle-speciﬁc phases of activation (67,68), the current
study supports an underlying role for differential regula-
tion of histone modiﬁcations through the cell cycle to
govern these actions. Together these data suggest the mag-
nitude of the CDKN1A activation, at least at early time
points, is inﬂuenced signiﬁcantly by the stage of the cell
cycle.
We added further to this understanding by establishing
VDR-dependent co-regulation of miR-106b to modulate
the precise timing of CDKN1A accumulation and also the
expression of p21
(waf1/cip1), and consequential cell cycle
arrest. Together these data demonstrate that VDR
induced regulation of p21
(waf1/cip1) is determined by inter-
play of histone modiﬁcations and miRNA expression that
combine in a feed-forward loop. Key regulatory aspects of
this loop are the re-distribution of VDR binding and
co-repressor associations to govern histone modiﬁcations
of two gene targets and the status of the cell cycle. The cell
Figure 6. In vivo regulation of Cdkn1a and miR-106b in murine
prostate. C57 BL/6xFVB WT mice were treated with 1a,25(OH)2D3
(20mg/kg) or equal volume of EtOH for 12 or 24h. Mice (n=9) in
each control and treatment group were sacriﬁced and the prostate
removed and pooled into three groups of three, mRNA extracted
using TRIzol (Invitrogen), and Cdkn1a and miR-106b levels were
measured by TaqMan Q-PCR. Accumulation of each target is given
as log2 (fold change). Each data point represents the mean±SEM.
A signiﬁcant induction of miR-106b was observed at 12h, and at 12
and 24h Cdkn1a was signiﬁcantly repressed. (**P<0.01).
Nucleic Acids Research,2011, Vol.39, No. 6 2053cycle component appears to open windows with which
other activators may exert an effect, for example p53, to
modulate the magnitude of effects. Given that the MCM7
gene is a key target of S-phase transcription factors such
as the E2F family members, this loop represents a balance
between transcription factors that promote either G1
arrest or S-phase progression (summarized in Figure 7).
Given that NR biology appears illustrative of basic mech-
anisms of transcription factor control the current ﬁndings
may apply generally to gene regulatory mechanisms.
The expression of miRNA contained within feed-
forward motifs is disrupted in cancer (69,70). For
example, the cellular advantage to retaining the MCM-7
promoter selectively in an active state (25) has recently
been underscored in prostate cancer by establishing that
miR-106b is a proto-oncogene (71). A strong emerging
literature now supports the concept that tumors changes
in miRNA regulation is translated to altered serum
expression and therefore offers an important diagnostic
and prognostic therapeutic window (72–75). In this
manner, the regulation of miRNA such as miR-106b in
feed-forward loop motifs may be critical biomarkers to
monitor VDR responsiveness. The current studies open
up the door to the possibility that serum expression of
VDR tumor-regulated miRNA deﬁne molecular
phenotypes associated with prostate cancer aggressiveness
and responsiveness to vitamin D compound treatment.
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